Physician profile
Anil Gupta
NPI 1154325694
$2,761.44
in general payments reported to CMS, 2019-2025
17 companies · $582 in 2025
The $582 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $245 · 2021: $306 · 2022: $325 · 2023: $517 · 2024: $356 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.67 |
| Education | $275.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $674.72 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $389.52 | 2019-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $350.98 | 2020-2025 | Nucala, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $275.97 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $219.86 | 2019-2022 | |
| Genzyme Corporation | $174.11 | 2023-2025 | |
| Csl Behring | $131.03 | 2020-2025 | Andembry |
| Avanir Pharmaceuticals, INC. | $115.00 | 2019 | |
| Amgen INC. | $101.93 | 2024-2025 | Tezspire |
| Lilly USA, LLC | $70.68 | 2020-2024 | Zepbound, Jardiance |
| Biocryst US Sales Co., LLC | $65.96 | 2023-2025 | Orladeyo |
| Amarin Pharma, INC. | $53.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.14 | 2024-2025 | |
| Exact Sciences Corporation | $31.33 | 2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $31.01 | 2025 | Edarbi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.47 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.